Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining ...

The European Commission has granted marketing authorization for Eylea 8mg (aflibercept 8mg, 114.3mg/ml solution for injection ...

European Commission grants marketing approval for Eylea 8 mg to treat macular edema following RVO, including branch, central and hemiretinal vein occlusion: Berlin Monday, January ...

The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Eylea HD improved vision with extended dosing intervals ...

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients with macular edema following ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

The firm now models $4.35 billion in U.S. Eylea franchise revenues for 2026, well above the $3.86 billion consensus. BofA also highlighted upside from Dupixent, noting it “continues to deliver growth” ...